Chemistry, UFMT, 2022
M. Sci., University of São Paulo (FFCLRP), 2025
Ph.D., USP/RP (current position)
Richard H. Lima born in 1999 in Igarapava, SP, Brazil. It is chemical focused on organic synthesis of medicinal interest. He obtained his degree in Chemistry from the Federal University of Triangulo Mineiro (UFTM, 2022), proposing the quantification of silver nanoparticle in a pharmaceutical product under the guidance of Profa. Dr. Valéria A. Alves. He concluded his master’s degree at the Faculty of Philosophy Sciences and Letters of the University of São Paulo (FFCL-RP_USP, 2025), developing compounds of the Nethyl-4-Piperidone derivative curcuminoid class to evaluate antimicrobial activity under the guidance of Prof. Dr. Antonio Eduardo Miller Crotti. Currently PhD Student at the Faculty of Pharmaceutical Sciences of the University of São Paulo (FCF_USP) in the group of Prof. Giuliano Clososki, his research explores directed functionalization aiming at the preparation of the new amino-intestinal amino-synthetic and medicinal interest.
Project title (PhD): Targeted functionalization aiming at the preparation of new amino-indolizines of synthetic and medicinal interest.
The study proposes the development of efficient methodologies for the introduction of amino groups into the indolizine core, an aromatic heterocycle of great relevance due to its pharmacological potential and applications in advanced materials. Amino-indolizines, the central focus of this investigation, are valuable structures as they serve as building blocks in the synthesis of more complex and bioactive molecules. The strategy involves the preparation of halogenated indolizine derivatives, obtained through both classical and modern routes, followed by palladium-catalyzed amination reactions inspired by the Buchwald–Hartwig methodology. In addition to enabling the synthesis of novel amino-indolizines, the research aims to expand the synthetic scope of this core, allowing the construction of functional libraries with potential impact on the development of new pharmaceuticals and high-performance materials.